title: MS as a gateway disease.
abstract: Multiple sclerosis (MS) clinical research has produced remarkable results over the past two decades leading to 9 marketed therapies that alter disease course. We have learned a great deal about the science of MS clinical trials, especially for treatments with anti-inflammatory agents. Moving forward, we would now like to apply what we have learned to the new challenges of treating the degenerative aspects of this illness. Doing so will have benefits not only for MS, but potentially for other neurodegenerative diseases.
authors.affiliation: The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY 10029-6574, United States. Electronic address: fred.lublin@mssm.edu.
authors.forename: Fred D
authors.initials: FD
authors.lastname: Lublin
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009410:Nerve Degeneration / Q000150:complications / Q000188:drug therapy*; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D018696:Neuroprotective Agents
keywords: Demyelination; Inflammation; Multiple sclerosis; Neurodegeneration